MASH: Promising Aspects from the Bench

Nov 09 2025
Convention Center: Ballroom A, Level 3
11:00 AM - 12:30 PM

World Class Speakers

Ekihiro Seki, MD, PhD, FAASLD
Abstract Presenter

Ekihiro Seki, MD, PhD, FAASLD

Cedars-Sinai Medical Center
Gyongyi Szabo, MD, PhD, FAASLD
Abstract Presenter

Gyongyi Szabo, MD, PhD, FAASLD

Beth Israel Deaconess Medical Center
Ekihiro Seki, MD, PhD, FAASLD
Moderator

Ekihiro Seki, MD, PhD, FAASLD

Cedars-Sinai Medical Center
Gyongyi Szabo, MD, PhD, FAASLD
Moderator

Gyongyi Szabo, MD, PhD, FAASLD

Beth Israel Deaconess Medical Center

Description

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Journey Maps

Presentations

11:00 AM - 11:15 AM
Aug 05 2026
Convention Center - Ballroom A, Level 3

Hepatocyte-macrophage crosstalk rewires liver zonation features in metabolic dysfunction-associated steatotic liver disease (MASLD)  

Ekihiro Seki, MD, PhD, FAASLD , Abstract Presenter
MASLD
11:15 AM - 11:30 AM
Aug 05 2026
Convention Center - Ballroom A, Level 3

Sexually Dimorphic Palmitoylation of UTY of Liver Sinusoidal Endothelial Cells Drives Advanced Metabolic Dysfunction-Associated Steatohepatitis (MASH) via PGF2α/SPIN1 Axis

Gyongyi Szabo, MD, PhD, FAASLD , Abstract Presenter
MASLD
11:30 AM - 11:45 AM
Aug 05 2026
Convention Center - Ballroom A, Level 3

Neutrophil Extracellular Traps Drive B Cell–Mediated Fibrogenesis in MASH by Silencing HES1 and Promoting Plasma Cell Differentiation

Ekihiro Seki, MD, PhD, FAASLD , Abstract Presenter
MASLD
11:45 AM - 12:00 PM
Aug 05 2026
Convention Center - Ballroom A, Level 3

Generation of multilineage, highly vascularized liver organoids enable disease modelling and exhibit transplantation potential

Gyongyi Szabo, MD, PhD, FAASLD , Abstract Presenter
MASLD
12:00 PM - 12:15 PM
Aug 05 2026
Convention Center - Ballroom A, Level 3

Deletion of LYPLAL1 Reduces Cellular Uptake of Fatty Acids and Promotes Mitochondrial β-oxidation to Protect Against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Ekihiro Seki, MD, PhD, FAASLD , Abstract Presenter
MASLD
12:15 PM - 12:30 PM
Aug 05 2026
Convention Center - Ballroom A, Level 3

Loss of Dnmt1 in hepatocytes promotes inflammation and fibrosis during MASLD/MASH development in mice

Gyongyi Szabo, MD, PhD, FAASLD , Abstract Presenter
MASLD

Objectives

  • Highlight emerging mechanistic insights and molecular pathways implicated in MASH pathogenesis that may inform novel therapeutic targets.
  • Present preclinical data and innovative experimental models contributing to the understanding and future management of MASH.